Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Michael Wachs to Immunosuppressive Agents

This is a "connection" page, showing publications Michael Wachs has written about Immunosuppressive Agents.

 
Connection Strength
 
 
 
0.577
 
  1. Kelly MA, Kaplan M, Nydam T, Wachs M, Bak T, Kam I, Zimmerman MA. Sirolimus reduces the risk of significant hepatic fibrosis after liver transplantation for hepatitis C virus: a single-center experience. Transplant Proc. 2013 Nov; 45(9):3325-8.
    View in: PubMed
    Score: 0.084
  2. Zimmerman MA, Kelly MA, Campsen J, Mandell MS, Wachs M, Bak T, Skibba A, Lancaster B, Kam I. The influence of OKT3 therapy on hepatocellular carcinoma recurrence following liver transplantation. Clin Transplant. 2010 Jul-Aug; 24(4):E103-8.
    View in: PubMed
    Score: 0.067
  3. Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Skibba A, Kam I. Sirolimus-based immunosuppression following liver transplantation for hepatocellular carcinoma. Liver Transpl. 2008 May; 14(5):633-8.
    View in: PubMed
    Score: 0.057
  4. Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Mandell S, Kam I. Sirolimus and liver transplantation: clinical implications for hepatocellular carcinoma. Expert Opin Pharmacother. 2007 Jun; 8(9):1275-82.
    View in: PubMed
    Score: 0.054
  5. Chonchol M, Wachs M, Taylor J, Popovtzer MM. Should we biopsy kidneys of patients post-liver transplant? Transplant Proc. 2003 Dec; 35(8):3035-8.
    View in: PubMed
    Score: 0.042
  6. Kugelmas M, Spiegelman P, Osgood MJ, Young DA, Trotter JF, Steinberg T, Wachs ME, Bak T, Kam I, Everson GT. Different immunosuppressive regimens and recurrence of primary sclerosing cholangitis after liver transplantation. Liver Transpl. 2003 Jul; 9(7):727-32.
    View in: PubMed
    Score: 0.041
  7. Dunkelberg JC, Trotter JF, Wachs M, Bak T, Kugelmas M, Steinberg T, Everson GT, Kam I. Sirolimus as primary immunosuppression in liver transplantation is not associated with hepatic artery or wound complications. Liver Transpl. 2003 May; 9(5):463-8.
    View in: PubMed
    Score: 0.040
  8. Trotter JF, Stolpman N, Wachs M, Bak T, Kugelmas M, Kam I, Everson GT. Living donor liver transplant recipients achieve relatively higher immunosuppressant blood levels than cadaveric recipients. Liver Transpl. 2002 Mar; 8(3):212-8.
    View in: PubMed
    Score: 0.037
  9. Trotter JF, Wachs ME, Trouillot TE, Bak T, Kugelmas M, Kam I, Everson G. Dyslipidemia during sirolimus therapy in liver transplant recipients occurs with concomitant cyclosporine but not tacrolimus. Liver Transpl. 2001 May; 7(5):401-8.
    View in: PubMed
    Score: 0.035
  10. Trotter JF, Wachs M, Bak T, Trouillot T, Stolpman N, Everson GT, Kam I. Liver transplantation using sirolimus and minimal corticosteroids (3-day taper). Liver Transpl. 2001 Apr; 7(4):343-51.
    View in: PubMed
    Score: 0.035
  11. Stegall MD, Wachs ME, Everson G, Steinberg T, Bilir B, Shrestha R, Karrer F, Kam I. Prednisone withdrawal 14 days after liver transplantation with mycophenolate: a prospective trial of cyclosporine and tacrolimus. Transplantation. 1997 Dec 27; 64(12):1755-60.
    View in: PubMed
    Score: 0.028
  12. Campsen J, Zimmerman MA, Trotter JF, Wachs M, Bak T, Steinberg T, Kaplan M, Wright F, Kam I. Liver transplantation for autoimmune hepatitis and the success of aggressive corticosteroid withdrawal. Liver Transpl. 2008 Sep; 14(9):1281-6.
    View in: PubMed
    Score: 0.015
  13. Zimmerman MA, Trotter JF, Wachs M, Bak T, Campsen J, Wright F, Steinberg T, Bennett W, Kam I. Predictors of long-term outcome following liver transplantation for hepatocellular carcinoma: a single-center experience. Transpl Int. 2007 Sep; 20(9):747-53.
    View in: PubMed
    Score: 0.013
  14. Kugelmas M, Osgood MJ, Trotter JF, Bak T, Wachs M, Forman L, Kam I, Everson GT. Hepatitis C virus therapy, hepatocyte drug metabolism, and risk for acute cellular rejection. Liver Transpl. 2003 Nov; 9(11):1159-65.
    View in: PubMed
    Score: 0.010
  15. Wiseman AC, Kam I, Christians U, Jani A, Bak T, Wachs M, Chan L. Fixed-dose sirolimus with reduced dose calcineurin inhibitor: the University of Colorado experience. Transplant Proc. 2003 May; 35(3 Suppl):122S-124S.
    View in: PubMed
    Score: 0.010
  16. Trouillot TE, Shrestha R, Kam I, Wachs M, Everson GT. Successful withdrawal of prednisone after adult liver transplantation for autoimmune hepatitis. Liver Transpl Surg. 1999 Sep; 5(5):375-80.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2025 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)